Carbidopa Anhydrous
The anhydrous form of carbidopa is used in combination with levodopa to manage the symptoms of Parkinson's disease, including tremors, stiffness, and slowness of movement. By inhibiting peripheral dopa decarboxylase, it increases the availability of levodopa in the brain. This form is chemically equivalent to the hydrated form but contains no bound water molecules.
Masse moléculaire
226,2300 g/mol
LogP
-2,20
TPSA
116,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Structure 2D
Cite this structure
Embed this structure
SMILES
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
InChI
InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
Molecular Formula
C10H14N2O4
HBD / HBA
5 / 6
Liaisons Rotatives
4
Atomes Lourds
16
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
The anhydrous form of carbidopa is used in combination with levodopa to manage the symptoms of Parkinson's disease, including tremors, stiffness, and slowness of movement. By inhibiting peripheral dopa decarboxylase, it increases the availability of levodopa in the brain. This form is chemically equivalent to the hydrated form but contains no bound water molecules.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Carbidopa Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201236. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 34359. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carbidopa-anhydrous"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carbidopa-anhydrous/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carbidopa-anhydrous/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carbidopa-anhydrous/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carbidopa-anhydrous"></drugfyi-drug>